Next Generation Complement Therapeutics: Potential Life-Changing Therapies for Multiple Rare Disorders
Roots Analysis
MARCH 3, 2022
Since the approval of Soliris® in 2007, an anti-C5 antibody, the field of complement drug discovery has gained significant attention. The complement-targeted therapeutics inhibit complement activation, thereby reducing tissue inflammation and dampening the adaptive immune response to foreign and tissue antigens.
52 
Let's personalize your content